Printer Friendly

ARES-SERONO GROUP REPORTS 1991 SALES IN EXCESS OF 1 BILLION SWISS FRANCS

ARES-SERONO GROUP REPORTS 1991 SALES IN EXCESS OF 1 BILLION SWISS FRANCS
 BOSTON, Jan. 20 /PRNewswire/ -- The Ares-Serono Group today reported worldwide sales of US$751 million (SFr. 1.071 billion) for the year ending Dec. 31, 1991, compared with $653.1 million last year, an increase of 15 percent. Excluding unfavorable currency fluctuations, sales growth for the year was 17.5 percent.
 "1991 sales in excess of 1 billion Swiss Francs is a significant achievement for the Group. With a compound annual growth rate of 27.0 percent during the last five years, Ares-Serono continues to exceed industry averages," said Fabio Bertarelli, chief executive officer of The Ares-Serono Group.
 Pharmaceutical sales for the year increased by 15.5 percent to $625.2 million from $541.5 million in 1990. After adjusting for unfavorable currency fluctuations, the growth in sales of pharmaceutical products was 17.8 percent.
 Sales in each of the Group's three main therapeutic areas -- infertility, immunology and pediatric endocrinology -- grew by almost 20 percent compared to the prior year. The Group expanded its worldwide position in the human fertility market, while sales of Saizen(R), a recombinant DNA human growth hormone, the Group's first genetically engineered product, and Frone(R), Ares-Serono's native beta-interferon, were particularly strong.
 On a geographical basis, significant sales growth occurred in the major European markets and the United States.
 In 1991, 65 new drug registrations were obtained worldwide.
 In the diagnostic division, sales increased from $97.2 million in 1990 to $106.7 million, an increase of 9.8 percent or 12.5 percent if unfavorable currency fluctuations are excluded. Growth in the diagnostic division resulted primarily from increased sales of SR-1 instruments and reagents.
 Sales of over-the-counter (OTC) products in 1991 were $19.1 million compared to $14.4 million in 1990, an increase of 32.6 percent over the prior year.
 The Ares-Serono Group employed 3,973 people at the end of 1991, compared with 3,828 at the end of 1990.
 The Ares-Serono Group is a leading Swiss developer and marketer of pharmaceutical and diagnostic products with executive headquarters in Geneva, Switzerland, and operating headquarters in Boston. The Group operates subsidiaries and manufacturing facilities in more than 20 countries. Shares of Ares-Serono S.A., the parent company of the Group, are listed on the major Swiss stock exchanges.
 -0- 1/20/92
 /CONTACT: Gina Cella of Ares-Serono, 617-982-9000, ext. 251/ CO: The Ares-Serono Group ST: Massachusetts IN: MTC SU:


SH -- NE004 -- 1321 01/20/92 09:26 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 20, 1992
Words:418
Previous Article:REPUBLIC WASTE COMPLETES ACQUISITION OF EVERGREEN ENVIRONMENTAL GROUP, INC. AND APPOINTS SENIOR V.P. OF HAZWASTE OPERATION
Next Article:IMT CHAIRMAN STEPS DOWN
Topics:


Related Articles
THE ARES-SERONO GROUP REPORTS THIRD QUARTER AND NINE MONTHS SALES AND EARNINGS
THE ARES-SERONO GROUP REPORTS 1991 NET EARNINGS OF US$71.2 MILLION
THE ARES-SERONO GROUP REPORTS SALES AND EARNINGS FOR THE FIRST QUARTER OF 1992
THE ARES SERONO GROUP REPORTS SECOND QUARTER AND FIRST HALF 1992 RESULTS
THE ARES SERONO GROUP REPORTS THIRD QUARTER AND NINE MONTHS SALES AND EARNINGS
THE ARES-SERONO GROUP REPORTS CONTINUED SALES GROWTH IN 1992
THE ARES-SERONO GROUP REPORTS INCREASED EARNINGS FOR 1992
ARES-SERONO NINE MONTH RESULTS: LOCAL SALES LEVEL MAINTAINED; NEW PRODUCT ADVANCEMENTS
ARES-SERONO ANNOUNCES SALES FOR 1993 AND SUCCESSFUL LAUNCH OF METRODIN HP(R)
THE ARES-SERONO GROUP REPORTS EARNINGS FOR 1993

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters